vs

Side-by-side financial comparison of Ispire Technology Inc. (ISPR) and AVITA Medical, Inc. (RCEL). Click either name above to swap in a different company.

Ispire Technology Inc. is the larger business by last-quarter revenue ($20.3M vs $17.6M, roughly 1.2× AVITA Medical, Inc.). Ispire Technology Inc. runs the higher net margin — -32.5% vs -66.0%, a 33.4% gap on every dollar of revenue. On growth, AVITA Medical, Inc. posted the faster year-over-year revenue change (-4.3% vs -51.5%). Ispire Technology Inc. produced more free cash flow last quarter ($-4.0M vs $-6.1M). Over the past eight quarters, AVITA Medical, Inc.'s revenue compounded faster (26.0% CAGR vs -17.8%).

Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...

ISPR vs RCEL — Head-to-Head

Bigger by revenue
ISPR
ISPR
1.2× larger
ISPR
$20.3M
$17.6M
RCEL
Growing faster (revenue YoY)
RCEL
RCEL
+47.2% gap
RCEL
-4.3%
-51.5%
ISPR
Higher net margin
ISPR
ISPR
33.4% more per $
ISPR
-32.5%
-66.0%
RCEL
More free cash flow
ISPR
ISPR
$2.1M more FCF
ISPR
$-4.0M
$-6.1M
RCEL
Faster 2-yr revenue CAGR
RCEL
RCEL
Annualised
RCEL
26.0%
-17.8%
ISPR

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
ISPR
ISPR
RCEL
RCEL
Revenue
$20.3M
$17.6M
Net Profit
$-6.6M
$-11.6M
Gross Margin
17.1%
81.2%
Operating Margin
-33.9%
-59.1%
Net Margin
-32.5%
-66.0%
Revenue YoY
-51.5%
-4.3%
Net Profit YoY
17.4%
-0.3%
EPS (diluted)
$-0.12
$-0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ISPR
ISPR
RCEL
RCEL
Q4 25
$20.3M
$17.6M
Q3 25
$30.4M
$17.1M
Q2 25
$20.1M
$18.4M
Q1 25
$26.2M
$18.5M
Q4 24
$41.8M
$18.4M
Q3 24
$39.3M
$19.5M
Q2 24
$37.3M
$15.2M
Q1 24
$30.0M
$11.1M
Net Profit
ISPR
ISPR
RCEL
RCEL
Q4 25
$-6.6M
$-11.6M
Q3 25
$-3.3M
$-13.2M
Q2 25
$-14.8M
$-9.9M
Q1 25
$-10.9M
$-13.9M
Q4 24
$-8.0M
$-11.6M
Q3 24
$-5.6M
$-16.2M
Q2 24
$-3.5M
$-15.4M
Q1 24
$-5.9M
$-18.7M
Gross Margin
ISPR
ISPR
RCEL
RCEL
Q4 25
17.1%
81.2%
Q3 25
17.0%
81.3%
Q2 25
12.3%
81.2%
Q1 25
18.2%
84.7%
Q4 24
18.5%
87.6%
Q3 24
19.5%
83.7%
Q2 24
28.3%
86.1%
Q1 24
20.4%
86.4%
Operating Margin
ISPR
ISPR
RCEL
RCEL
Q4 25
-33.9%
-59.1%
Q3 25
-8.9%
-53.6%
Q2 25
-72.7%
-60.5%
Q1 25
-40.4%
-63.9%
Q4 24
-17.6%
-54.1%
Q3 24
-13.4%
-70.6%
Q2 24
-9.2%
-102.8%
Q1 24
-18.8%
-155.0%
Net Margin
ISPR
ISPR
RCEL
RCEL
Q4 25
-32.5%
-66.0%
Q3 25
-10.7%
-77.3%
Q2 25
-73.4%
-53.9%
Q1 25
-41.5%
-74.9%
Q4 24
-19.1%
-63.0%
Q3 24
-14.2%
-82.9%
Q2 24
-9.4%
-101.3%
Q1 24
-19.7%
-168.0%
EPS (diluted)
ISPR
ISPR
RCEL
RCEL
Q4 25
$-0.12
$-0.37
Q3 25
$-0.06
$-0.46
Q2 25
$-0.26
$-0.38
Q1 25
$-0.19
$-0.53
Q4 24
$-0.14
$-0.44
Q3 24
$-0.10
$-0.62
Q2 24
$-0.07
$-0.60
Q1 24
$-0.11
$-0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ISPR
ISPR
RCEL
RCEL
Cash + ST InvestmentsLiquidity on hand
$17.6M
$18.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$-7.7M
$-16.6M
Total Assets
$84.4M
$56.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ISPR
ISPR
RCEL
RCEL
Q4 25
$17.6M
$18.2M
Q3 25
$22.7M
$23.3M
Q2 25
$24.4M
$15.7M
Q1 25
$23.5M
$25.8M
Q4 24
$34.4M
$35.9M
Q3 24
$37.7M
$44.4M
Q2 24
$35.1M
$54.1M
Q1 24
$39.5M
$68.2M
Stockholders' Equity
ISPR
ISPR
RCEL
RCEL
Q4 25
$-7.7M
$-16.6M
Q3 25
$-1.8M
$-6.7M
Q2 25
$604.7K
$-12.9M
Q1 25
$14.8M
$-4.6M
Q4 24
$24.2M
$4.5M
Q3 24
$30.7M
$12.2M
Q2 24
$34.5M
$23.9M
Q1 24
$35.9M
$32.6M
Total Assets
ISPR
ISPR
RCEL
RCEL
Q4 25
$84.4M
$56.4M
Q3 25
$96.4M
$63.7M
Q2 25
$102.2M
$58.1M
Q1 25
$115.7M
$69.6M
Q4 24
$132.0M
$79.7M
Q3 24
$129.0M
$81.1M
Q2 24
$122.6M
$87.8M
Q1 24
$108.0M
$97.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ISPR
ISPR
RCEL
RCEL
Operating Cash FlowLast quarter
$-4.0M
$-5.4M
Free Cash FlowOCF − Capex
$-4.0M
$-6.1M
FCF MarginFCF / Revenue
-19.9%
-34.7%
Capex IntensityCapex / Revenue
0.3%
3.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-14.2M
$-33.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ISPR
ISPR
RCEL
RCEL
Q4 25
$-4.0M
$-5.4M
Q3 25
$-1.2M
$-5.2M
Q2 25
$4.7M
$-10.2M
Q1 25
$-12.5M
$-10.3M
Q4 24
$-3.2M
$-8.1M
Q3 24
$3.6M
$-7.2M
Q2 24
$-1.4M
$-12.8M
Q1 24
$3.4M
$-20.9M
Free Cash Flow
ISPR
ISPR
RCEL
RCEL
Q4 25
$-4.0M
$-6.1M
Q3 25
$-1.2M
$-6.2M
Q2 25
$3.7M
$-10.8M
Q1 25
$-12.7M
$-10.5M
Q4 24
$-3.2M
$-9.7M
Q3 24
$3.3M
$-11.0M
Q2 24
$-2.2M
$-15.4M
Q1 24
$3.3M
$-22.0M
FCF Margin
ISPR
ISPR
RCEL
RCEL
Q4 25
-19.9%
-34.7%
Q3 25
-3.9%
-36.1%
Q2 25
18.6%
-58.4%
Q1 25
-48.4%
-56.9%
Q4 24
-7.7%
-52.7%
Q3 24
8.5%
-56.1%
Q2 24
-5.9%
-101.6%
Q1 24
10.9%
-198.2%
Capex Intensity
ISPR
ISPR
RCEL
RCEL
Q4 25
0.3%
3.8%
Q3 25
0.0%
5.5%
Q2 25
4.8%
2.8%
Q1 25
0.7%
1.2%
Q4 24
0.1%
8.8%
Q3 24
0.7%
19.2%
Q2 24
2.0%
17.5%
Q1 24
0.3%
10.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons